Dr. Danilov is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Division of Lymphoma
1500 East Duarte Road
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-389-3058
Summary
- Dr. Danilov earned his medical degree in Russia and completed a fellowship in hematology/oncology at Tufts Medical Center, in Boston, United States. He is a physician-scientist with background in molecular biology and cancer cell signaling and expertise in oncologic drug development. He leads an independent research program in B-cell malignancies which bridges the understanding of B-cell biology with early clinical evaluation of novel therapeutics.
As a Director of Early Phase Therapeutics Program and a leader of the Lymphoma Center, Dr. Danilov guides an effort in experimental therapeutics at the City of Hope National Medical Center. His group’s pre-clinical focus is on evaluation of novel targets in the ubiquitin-proteasome system and oncogenic role of cyclin-dependent kinase-9. In addition, his group performs correlative science on multiple clinical trials. He received peer-reviewed funding from the National Cancer Institute (R01), Leukemia and Lymphoma Society, American Society of Hematology and Lymphoma Research Foundation, and serves as Co-Chair for Translational Medicine of the Southwest Oncology Group Lymphoma Committee.
Clinically, Dr. Danilov is a practicing medical oncologist specializing in the care of patients with CLL and lymphoma. Building on his pre-clinical discoveries, he launched multiple early-phase clinical trials with novel agents. As a member of industry and SWOG committees and a leader within the Early Therapeutics Clinical Trials Network, he participates in drug development on a global scale.
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
- Brown UniversityResidency, Internal Medicine, 2004 - 2007
- Yaroslavl Med AcadClass of 1997
Certifications & Licensure
- CA State Medical License 2019 - 2025
- OR State Medical License 2014 - 2023
- NH State Medical License 2010 - 2015
- RI State Medical License 2005 - 2007
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Leukemia and Lymphoma Society Scholar LLS, 2018
Clinical Trials
- Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma Start of enrollment: 2019 Feb 26
Roles: Contact, Principal Investigator
- Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2021 Mar 16
Roles: Principal Investigator, Contact
- Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Start of enrollment: 2022 Jun 29
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.Matthew S Davids, Danielle M Brander, Yesid Alvarado Valero, Catherine Sibyl Diefenbach, Daniel Nathan Egan
Blood Advances. 2024-12-20 - Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia.Michele D Stanchina, Skye Montoya, Alexey V Danilov, Jorge J Castillo, Alvaro J Alencar
Nature Reviews. Clinical Oncology. 2024-12-01 - Bruton Tyrosine Kinase Degraders in B-Cell Malignancies.Tiana Huynh, Sonia Rodriguez-Rodriguez, Alexey V Danilov
Molecular Cancer Therapeutics. 2024-05-02
Press Mentions
- Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline SettingDecember 9th, 2024
- Promising Results with Epcoritamab Monotherapy in Relapsed/Refractory CLLDecember 8th, 2024
- Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary AnalysisDecember 8th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: